[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregabalin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregabalin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,68,88,114,133,153,180,201,220,239,254,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100605079","the-efficacy-and-safety-of-pregabalin-and-mirogabalin-in-patients-with-fibromyalgia-100605079",false,"NCT07157852","The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Mirogabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Newly diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\\[1\\]\n* Aged over 18 years old;\n* Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM;\n* Baseline numeric rating scale (NRS) score of 4 or higher;\n* Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range;\n* Estimated glomerular filtration rate (eGFR) of at least 30 mL\u002Fmin\u002F1.73 m²;\n* Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements;\n\nExclusion Criteria:\n\n* Previous allergic reactions to pregabalin, mirogabalin, or any of their excipients;\n* Prior diagnosis of epilepsy or depression requiring antidepressant therapy;\n* Women who are pregnant or breastfeeding;\n* Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment;\n* Suffering from acute or chronic pain disorders other than FM.","ALL","18 Years",{"count":19,"type":20},674,"ESTIMATED","INTERVENTIONAL",[23],"NA","Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Mirogabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or mirogabalin in treating FM, with the aim of providing a better treatment option for FM patients.",[26,27,28,29],"Fibromyalgia","Pregabalin","Mirogabalin","Pain","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2025-09-05",{"date":38,"type":20},"2027-08-31",{"name":40,"class":41},"Beijing Tiantan Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100614143","phase-2-y-4-to-treat-the-postherpetic-neuralgia-100614143","NCT07275762","Y-4 to Treat the Postherpetic Neuralgia","A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Y-4 Tablets in Chinese Patients With Postherpetic Neuralgia, Compared With Pregabalin Capsules","Inclusion Criteria:\n\n\\- 1. Able to understand and voluntarily sign the informed consent form. 2. Age ≥ 18 years, any gender. 3. Diagnosed with PHN, meaning pain persists for more than one month after the acute shingles rash has healed.\n\n4\\. VAS score in SF-MPQ ≥ 40 mm of the last 24 hours during screening.\n\nExclusion Criteria:\n\n* 1\\. Known previous allergy to the investigational products, rescue medication ingredients, other chemically similar drugs, or excipients.\n\n  2\\. During screening, individuals who have been clearly diagnosed with peripheral neuropathy or pain unrelated to PHN (including but not limited to those caused by cerebrovascular disease, Guillain-Barré syndrome, cervical or lumbar spine disorders, osteoarticular or tendon lesions, chronic kidney disease or uremia, thyroid disease, intracranial tumors, trauma, etc.) and are judged by the investigator to potentially confound the assessment of PHN.\n\n  3\\. During screen, suffer from a systemic disease that, in the opinion of the investigator, may affect the patient's participation in the study or affect the evaluation of the efficacy of PHN, including but not limited to:\n  1. Severe cardiopulmonary diseases, such as unstable angina, myocardial infarction, severe arrhythmia within 6 months prior to screening, NYHA cardiac function classification of grade III\\~IV at screening, hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg at screening), recurrent asthma attacks, etc.;\n  2. Chronic digestive diseases, such as liver fibrosis, chronic active hepatitis, peptic ulcer, etc.;\n  3. Neuropsychiatric disorders, including epilepsy, recurrent dizziness or headache, cognitive impairment; Cerebrovascular disease (such as cerebral infarction) or recurrent transient ischemic attack within 6 months prior to screening;\n  4. History of malignant tumors within 5 years prior to screening (excluding cured basal cell carcinoma of the skin, carcinoma in situ and papillary thyroid carcinoma);\n  5. Presence of active infection, which, in the opinion of the investigator, is not suitable for entry into this study;\n  6. Diabetic patients with poor glycemic control (peritoneal venous blood glucose ≥11mmol\u002FL at screening);\n  7. Suffering from immunocompromised diseases, such as systemic lupus erythematosus, acquired immunodeficiency syndrome, immunosuppressant therapy for autoimmune diseases.\n\n  4\\. During screening, situations may exist that investigators believe could affect pain assessment, such as if the affected skin area has a skin condition that may influence sensation.\n\n  5\\. Previously received nerve destruction for PHN, or underwent minimally invasive interventions (such as nerve blocks or neurostimulation), physical therapy (such as red light therapy), or traditional Chinese external treatments (such as acupuncture) within one week prior to screening.\n\n  6\\. Use prohibited drugs within the first 5 half-lives, or change the restricted drug dosage within the first 14 days.\n\n  7\\. Severe hematological, hepatatological, and renal function abnormalities at the time of screening, which meet any of the following laboratory test results: 1) Hematology: neutrophil count \\\u003C 1.5×109\u002FL, or platelet \\\u003C 90×109\u002FL, or hemoglobin \\\u003C100g\u002FL; 2) Liver function: ALT or AST \\> 2.5 times ULN; or TBIL \\> 1.5 times ULN; 3) Renal function: CrCL\\\u003C60 mL\u002Fmin\u002F1.73 m2 (calculated based on Cockroft-Gault formula a); 4) Creatine kinase \\>2-fold ULN.\n\n  8\\. Participants already diagnosed with sleep apnea, or those with severe snoring and daytime sleepiness, as well as intermittent hypoxia.\n\n  9\\. Participants with a history of suicidal behavior, or those assessed to have suicidal tendencies using the Columbia-Suicide Severity Rating Scale (C-SSRS).\n\n  10.Hepatitis B surface antigen (HBsAg) positive and HBV-DNA titer \\>lower limit of reference value, or hepatitis C virus antibody (HCV-Ab) positive and HCV-DNA titer \\>lower limit of reference value, or human immunodeficiency virus antibody (HIV-Ab) positive, or serum Treponema pallidum-specific antibodies (TP-Ab) positiv eand rapid plasma reagin\u002Ftoluidine red unheated serum test (RPR or TRUST) positive at screening.\n\n  11\\. Known drug abuse, or history of alcohol abuse within 1 year prior to screening, i.e., drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine).\n\n  12\\. Pregnant or lactating females. 13.Male (or their partner) or female subjects have a fertility plan during the whole study period and within 1 month after the end of the study or are unwilling to take one or more non-drug contraceptive measures (such as condoms, intrauterine devices, etc.) during the study period.\n\n  14.Prior participation in any other clinical study of any other drug within 30 days prior to screening.\n\n  15.Engaging in high-altitude work, driving motor vehicles, or operating heavy machinery with associated risks during the study period.\n\n  16.Other conditions that are considered unsuitable by the investigator to participate in this clinical study.",{"count":51,"type":20},160,[53],"PHASE2","The goal of this clinical trial is to assess the efficacy and safety of Y-4 in patients with postherpetic neuralgia(PHN).\n\nThe main questions it aims to answer are: The efficacy and safety of Y-4 to treat PHN compared with pregabalin.\n\nResearchers will analyze data from different groups, includes Y-4 group and pregabalin group , to see efficacy of Y-4 and If drug Y-4 is safe and tolerate in the patients with PHN.\n\nParticipants will :\n\n* Take Y-4 (1w titration period: 75 mg pregabalin +18.75 mg riluzole, 12w fixed dose period: 150 mg pregabalin +37.5 mg riluzole, 1w drug withdraw period: 1w titration period: 75 mg pregabalin +18.75 mg riluzole) or pregabalin(75 mg for 1w titration period , 150 mg for 12w fixed dose period ,75 mg for 1w drug withdraw period) twice a day for 14 weeks after run-in period (placebo) lasting for 1 week.\n* Visit the hospital according to the follow-up schedule agreed upon with your doctor. contact the research staff as soon as possible to reschedule when unable to attend the scheduled study visit.\n* Use investigational products as directed by the doctor and undergo the related treatment.\n* Inform their investigators of any changes in their health, including any side effects or symptoms, whether or not they believe these changes are related to the trial medication, as well as any new medications they are using or wish to use, or any changes in the dosage of medications they have already taking.\n* Use reliable contraceptive methods , such as abstinence, intrauterine devices, double barrier methods (e.g., condom with spermicide or condom with a diaphragm containing spermicide), contraceptive implants, or oral contraceptives (except if the partner is infertile) during the study period and within one month after the study is completed.\n* Must inform investigators immediately if they or their partner become pregnant during the study.\n* Be sure to inform other doctors being consultant that you are participating in this clinical study.\n* Restrict medication use and treatment during the study.",[56,57,27],"Postherpetic Neuralgia","Y-4","2026-05-09",{"date":60,"type":34},"2026-05-13",{"date":62,"type":34},"2026-02-02",{"date":64,"type":20},"2026-11-30",{"name":66,"class":67},"Neurodawn Pharmaceutical Co., Ltd.","INDUSTRY",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":87,"locationsCount":42},"100610637","the-efficacy-and-safety-of-short-term-s-ketamine-infusion-as-an-adjunctive-therapy-in-patients-with-fibromyalgia-100610637","NCT07230171","The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Conventional Therapy With Conventional Therapy Combined Esketamine in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Patients between ages over 18 years with proper cognitive function and language skills for the study;\n* Patients diagnosed with FM as defined by the ACR FM diagnostic criteria;\n* Patients who have experienced insufficient symptom relief with non-pharmacological treatments and have not previously received recommended pharmacological treatment for FM;\n* A score of ≥ 4 on the average pain intensity over 7 days on the numeric rating scale (NRS) at baseline.\n\nExclusion criteria:\n\n* Patient refusal;\n* Inability to sign informed consent;\n* Had other secondary FM, this is, hypothyroidism, nutritional deficiency, diabetes mellitus, connective tissue disorder;\n* Had psychiatric disorder, this is, schizophrenia and other psychotic disorder, bipolar disorder, or personality disorder;\n* Obstructive sleep apnea syndrome or a STOP-Bang score ≥ 3;\n* History of treatment with pregabalin and\u002For venlafaxine for any disease;\n* History of treatment with intravenous ketamine or ESK for chronic pain;\n* Presence of other painful ailments such as inflammatory rheumatic disease;\n* Uncontrolled diabetes, refractory hypertension, malignancies, narrow-angle glaucoma, hyperthyroidism, severe cardiovascular disease or any other contraindications to esketamine;\n* History of prescription drug abuse, alcoholism or illicit drug use;\n* Pregnant or lactating women;\n* Allergic to any of the study drugs.",{"count":76,"type":20},92,[23],"Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.",[26,27,80],"Esketamine","2026-05-03",{"date":83,"type":34},"2026-05-07",{"date":85,"type":34},"2025-09-15",{"date":38,"type":20},{"name":40,"class":41},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":17,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":112,"locationsCount":42},"100625345","adding-amantadine-or-duloxetine-to-pregabalin-on-occurrence-of-post-mastectomy-pain-syndrome-100625345","NCT07421427","Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome","The Effect of Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome; Randomized Controlled Study","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* American society of anesthesiologists (ASA) Physical status II, III.\n* Body mass index (BMI): (20-40) kg\u002Fm2.\n* Type of surgery: patients undergoing modified radical mastectomy for breast cancer.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with Known sensitivity or contraindication to drug used in the study.\n* History of psychological disorders and\u002For chronic pain and drug abuse patients.\n* Previous administration of antidepressants, anticonvulsants, or opioids before surgery.\n* Severe respiratory or cardiac disorders.\n* Advanced liver or kidney disease.\n* Previous breast surgery","FEMALE","65 Years",{"count":98,"type":20},150,[23],"This study aims to evaluate the additive effect of Amantadine or Duloxetine to Pregabalin on development of post mastectomy pain syndrome",[102,103,27,104,105],"Amantadine","Duloxetine","Mastectomy","Pain Syndrome","2026-02-21",{"date":108,"type":34},"2026-02-24",{"date":106,"type":34},{"date":111,"type":20},"2027-01-01",{"name":113,"class":41},"Cairo University",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":132,"locationsCount":42},"100608061","the-efficacy-and-safety-of-pregabalin-and-crisugabalin-in-patients-with-fibromyalgia-100608061","NCT07196657","The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Crisugabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\n* Aged over 18 years old;\n* Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM;\n* Baseline numeric rating scale (NRS) score of 4 or higher;\n* Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range;\n* Estimated glomerular filtration rate (eGFR) of at least 30 mL\u002Fmin\u002F1.73 m²;\n* Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements;\n\nExclusion Criteria:\n\n* Previous allergic reactions to pregabalin, crisugabalin, or any of their excipients;\n* Prior diagnosis of epilepsy or depression requiring antidepressant therapy;\n* Women who are pregnant or breastfeeding;\n* Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment;\n* Suffering from acute or chronic pain disorders other than FM.",{"count":122,"type":20},1116,[23],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. crisugabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or crisugabalin in treating FM, with the aim of providing a better treatment option for FM patients.",[26,27,29],"2026-02-09",{"date":128,"type":34},"2026-02-11",{"date":130,"type":34},"2025-09-30",{"date":38,"type":20},{"name":40,"class":41},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":96,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":42},"100622384","efficacy-and-safety-of-pregabalintizanidine-vs-pregabalin-in-patients-with-fibromyalgia-100622384","NCT07382921","Efficacy and Safety of Pregabalin\u002FTizanidine vs. Pregabalin in Patients With Fibromyalgia","Efficacy and Safety of Pregabalin\u002FTizanidine vs. Pregabalin in Patients With Fibromyalgia: a Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) Trial","Inclusion Criteria:\n\n* 1.Aged 18-65 years. 2.Fulfill the 2016 updated American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia.\n\n  3.Sufficient cognitive function, visual acuity and language skills to complete questionnaires and pain diaries and to participate in telephone communication with study nurses to permit titration of the study drugs.\n\n  4.Experienced daily pain (≥4\u002F10 on a numerical rating scale) for at least 3 months.\n\nExclusion Criteria:\n\n* 1.Presence of a painful condition, including inflammatory rheumatic disease, more than 50% as severe as but distinct from fibromyalgia.\n\n  2.Women who are pregnant or lactating. 3.Women of childbearing potential not using adequate contraceptives. 4.End-stage kidney or liver disease. 5.Unstable cardiovascular disease (myocardial infarction within the preceding year, unstable angina, or congestive heart failure) or clinically relevant abnormal 12-lead electrocardiogram.\n\n  6.Any poorly controlled medical condition that, in the opinion of the investigator, would interfere with proper conduct of the trial.\n\n  7.Severe depression, as determined by a Beck Depression Inventory-II score of 29 or more suicidal ideation, as determined by a Beck Depression Inventory-II item 9 score of 2 or more any current major psychiatric disorder (e.g., schizophrenia, bipolar disorder) that is not well controlled.\n\n  8.Hypersensitivity to any of the study medications. 9.Any current alcohol or drug abuse or dependence (except nicotine and caffeine).\n\n  10.Those taking more than 90 mg morphine equivalents per day.",{"count":141,"type":20},164,[23],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common.Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist with skeletal muscle relaxant, sedative and anxiolytic properties.we carried out an open-label clinical trial in order to evaluate the efficacy and safety of combined treatment with tizanidine and pregabalin for pain in FM.",[26,27,29],"NOT_YET_RECRUITING",{"date":147,"type":34},"2026-02-04",{"date":149,"type":20},"2026-01-30",{"date":151,"type":20},"2026-08",{"name":40,"class":41},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":42},"100619426","oral-melatonin-versus-oral-pregabalin-on-postoperative-pain-and-anxiety-following-spine-surgery-100619426","NCT07344467","Oral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery","Effect of Oral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 21-60 years old.\n* Both sexes.\n* Patients of American Society of Anesthesiologists (ASA) physical status I \\& II.\n* Undergoing elective spine surgery.\n\nExclusion Criteria:\n\n* Patient refusal.\n* History of allergic reactions to melatonin or pregabalin.\n* Patients with cardiovascular disease (ischemic heart disease, Heart Failure, Arrythmia, Heart Block).\n* Patients with kidney disease with (plasma creatinine level \\> 1.5mg\u002Fdl).\n* Patients with liver disease with (aspartate transaminase, alanine transaminase, and bilirubin levels more than twice the upper limit of normal).\n* Psychological and cognitive disorders; dementia; major depression.\n* Circadian rhythm disorders such as chronic fatigue syndrome and drowsiness.","21 Years","60 Years",{"count":163,"type":20},105,[23],"This study aims to compare the efficacy of using Melatonin versus Pregabalin on postoperative pain and anxiety after spine surgeries.",[167,168,27,169,170,171],"Oral","Melatonin","Postoperative Pain","Anxiety","Spine Surgery","2026-01-17",{"date":174,"type":34},"2026-01-21",{"date":172,"type":34},{"date":177,"type":20},"2027-06-01",{"name":179,"class":41},"Tanta University",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":200},"100607299","the-efficacy-and-safety-of-pregabalin-combined-with-venlafaxine-in-patients-with-fibromyalgia-100607299","NCT07186751","The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy With Pregabalin Combined Other Neuromodulatory Drugs (Venlafaxine) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\n* Aged more than 18 years;\n* Suffering from moderate to severe FM with 11-point numeric rating scale (NRS) score more than 4 at baseline that have not been effectively alleviated by non-pharmacological treatments and has not received currently recommended pharmacological treatment for FM;\n* Agreed to sign the informed consent form.\n\nExclusion criteria\n\n* A history of psychiatric disease;\n* Hypersensitivity or have contraindications to pregabalin, venlafaxine;\n* Pregnancy or breastfeeding;\n* Presence of serious systemic diseases, including uncontrolled hypertension, uncontrolled diabetes, significant cardiac dysfunction, or chronic hepatic or renal dysfunction;\n* With acute or chronic pain conditions other than FM.",{"count":188,"type":20},750,[23],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs), such as duloxetine, has demonstrated efficacy in FM by modulating pain pathways through increased serotonin and norepinephrine availability. Several studies have highlighted benefits of venlafaxine in FM. We hypothesize that the combination of pregabalin with venlafaxine may offer greater pain relief compared pregabalin monotherapy, without a significant increase in adverse effects for patients with FM.",[26,27,192,29],"Venlafaxine","2026-01-14",{"date":195,"type":34},"2026-01-15",{"date":197,"type":34},"2025-09-20",{"date":38,"type":20},{"name":40,"class":41},2,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":218,"leadSponsor":219,"locationsCount":42},"100610639","the-efficacy-and-safety-of-pregabalin-combined-with-dexmedetomidine-in-patients-with-fibromyalgia-100610639","NCT07230197","The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy With Pregabalin Combined Dexmedetomidine in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\n* Aged 18 years or older;\n* Experiencing moderate to severe FM that have not been effectively alleviated by non-pharmacological treatments and has not received currently recommended pharmacological treatment for FM;\n* Numeric rating scale (NRS) score ≥ 4 at baseline;\n* Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion criteria\n\n* History of hypersensitivity to pregabalin, venlafaxine or any of its excipients;\n* History of epilepsy, or depression requiring antidepressant medications;\n* Pregnancy or breastfeeding;\n* Presence of serious systemic diseases, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac dysfunction;\n* With acute or chronic pain conditions other than FM.",{"count":209,"type":20},400,[23],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Dexmedetomidine, a highly selective α2-adrenergic receptors agonist, could improve sleep disorders, making it a possible treatment option for treating FM. The investigators hypothesize that the combination of pregabalin with dexmedetomidine may offer greater pain relief compared pregabalin monotherapy, without a significant increase in adverse effects for patients with FM.",[26,27,213],"Dexmedetomidine","2025-11-22",{"date":216,"type":34},"2025-11-28",{"date":130,"type":34},{"date":38,"type":20},{"name":40,"class":41},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":42},"100608961","the-efficacy-and-safety-of-pregabalin-combined-with-toludesvenlafaxine-in-patients-with-fibromyalgia-100608961","NCT07208357","The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy With Pregabalin Combined Other Neuromodulatory Drugs (Toludesvenlafaxine) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\n* Aged 18 years or older;\n* Experiencing moderate to severe FM that have not been effectively alleviated by non-pharmacological treatments and has not received currently recommended pharmacological treatment for FM;\n* Numeric rating scale (NRS) score ≥ 4 at baseline;\n* Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion criteria\n\n* History of hypersensitivity to pregabalin, toludesvenlafaxine or any of its excipients;\n* History of epilepsy, or depression requiring antidepressant medications;\n* Pregnancy or breastfeeding;\n* Presence of serious systemic diseases, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac dysfunction;\n* With acute or chronic pain conditions other than FM.",{"count":228,"type":20},384,[23],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs), such as duloxetine, has demonstrated efficacy in FM by modulating pain pathways through increased serotonin and norepinephrine availability. Several studies have highlighted benefits of toludesvenlafaxine in FM. We hypothesize that the combination of pregabalin with toludesvenlafaxine may offer greater pain relief compared pregabalin monotherapy, without a significant increase in adverse effects for patients with FM.",[26,27,103,29],"2025-11-13",{"date":234,"type":34},"2025-11-17",{"date":236,"type":34},"2025-10-20",{"date":38,"type":20},{"name":40,"class":41},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":253,"locationsCount":42},"100606113","the-efficacy-and-safety-of-pregabalin-combined-with-desvenlafaxine-in-patients-with-fibromyalgia-100606113","NCT07171320","The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy With Pregabalin Combined Other Neuromodulatory Drugs (Desvenlafaxine) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\n* Aged 18 years or older;\n* Experiencing moderate to severe FM that have not been effectively alleviated by non-pharmacological treatments and has not received currently recommended pharmacological treatment for FM;\n* Numeric rating scale (NRS) score ≥ 4 at baseline;\n* Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion criteria\n\n* History of hypersensitivity to pregabalin, desvenlafaxine or any of its excipients;\n* History of epilepsy, or depression requiring antidepressant medications;\n* Pregnancy or breastfeeding;\n* Presence of serious systemic diseases, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac dysfunction;\n* With acute or chronic pain conditions other than FM.",{"count":228,"type":20},[23],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs), such as duloxetine and venlafaxine, have demonstrated efficacy in FM by modulating pain pathways through increased serotonin and norepinephrine availability. Desvenlafaxine, the third SNRI, was found with lower adverse effects compared with duloxetine and venlafaxine. We hypothesize that the combination of pregabalin with desvenlafaxine may offer greater pain relief compared pregabalin monotherapy, without a significant increase in adverse effects for patients with FM.",[26,27,29],{"date":234,"type":34},{"date":85,"type":34},{"date":38,"type":20},{"name":40,"class":41},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":42},"100488464","phase-4-pregabalin-versus-dexmedetomidine-for-delirium-treatment-after-coronary-artery-bypass-grafting-100488464","NCT05640453","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting: A Randomized Double-Blind Trial","Inclusion Criteria:\n\n* CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD).\n\nExclusion Criteria:\n\n* Patients who had history of psychiatric diseases; inability to communicate;\n* previous history of POD; preoperative sick sinus syndrome, allergy\u002Fsensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \\\u003C50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency.\n* Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.",{"count":262,"type":20},70,[264],"PHASE4","The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.",[27,267,268,213],"Delirium Treatment","Coronary Artery Bypass Grafting","2025-06-23",{"date":271,"type":34},"2025-06-25",{"date":273,"type":34},"2022-12-15",{"date":275,"type":20},"2026-05-15",{"name":179,"class":41},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":42},"100500378","effects-of-oxycodone-combined-with-pregabalin-on-chronic-postsurgical-pain-in-spinal-surgery-100500378","NCT05795478","Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery","Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery: a Randomized Control, Double-blinded, Factorial Design Trial","Inclusion Criteria:\n\n* Patient undergoing elective spinal surgery\n* Ages equal to or more than 18 years old\n* ASA I-III\n* Signed informed consent\n\nExclusion Criteria:\n\n* Previous allergic history to gabapentinoids or oxycodone;\n* Patients with aphasia or inability to cooperate with scales assessments;\n* Patients with a diagnosed history of psychiatric disorder;\n* Known severe insufficiency of vitals(such as heart failure\u002Frenal dysfunction\u002Fhepatic failure);\n* Patients treated with gabapentin\u002Fpregabalin in the last three months;\n* History of drug abuse;\n* Body Mass Index more than 35 kg\u002F㎡;\n* Pregnant or breastfeeding woman.",{"count":285,"type":20},264,[23],"Chronic postoperative pain is one of the common perioperative complications, which seriously affects the prognosis of patients. Currently, no specific perioperative pain management strategy has been found to be effective in preventing and treating chronic postoperative pain in patients undergoing spinal surgery. At present, oxycodone has been widely recognized in different surgical populations for the control of acute postoperative pain, but its contribution to chronic postoperative pain remains unknown. Meanwhile, whether pregabalin can reduce the occurrence of chronic postoperative pain remains controversial, and whether the combination of the two drugs can control the occurrence of chronic postoperative pain in a more comprehensive way remains unknown. Therefore, we intend to conduct this randomized-controlled, factorial design study to determine the efficacy and safety of oxycodone combined with pregabalin in the treatment of chronic postoperative pain in patients undergoing spinal surgery.",[289,290,27,291],"Chronic Post Operative Pain","Oxycodone","Postoperative Complications","2024-07-31",{"date":294,"type":34},"2024-08-01",{"date":296,"type":34},"2023-10-24",{"date":298,"type":20},"2024-12-31",{"name":40,"class":41}]